Bayer Inc.

Meetings over time

• Aug 20251 meetingNoemie Fiset-Tremblay
  Aug 2025: 1 meeting, with Noemie Fiset-Tremblay
• Sep 20250 meetings
  Sep 2025: 0 meetings
• Oct 20255 meetingsAnna Roberts, Miro Froehlich, Chris Bittle, Tom Kmiec, Parm Bains
  Oct 2025: 5 meetings, with Anna Roberts, Miro Froehlich, Chris Bittle, Tom Kmiec, Parm Bains
• Nov 20250 meetings
  Nov 2025: 0 meetings
• Dec 20251 meetingManuela Tomic
  Dec 2025: 1 meeting, with Manuela Tomic
• Jan 20260 meetings
  Jan 2026: 0 meetings
• Feb 20263 meetingsLawrence Hanson, Serena Smith, Nathalie Gour, Arran McPherson, Justine Frame
  Feb 2026: 3 meetings, with Lawrence Hanson, Serena Smith, Nathalie Gour, Arran McPherson, Justine Frame
• Mar 20261 meetingManuela Tomic
  Mar 2026: 1 meeting, with Manuela Tomic
• Apr 20260 meetings
  Apr 2026: 0 meetings
• May 20261 meetingManuela Tomic, David McFarlane
  May 2026: 1 meeting, with Manuela Tomic, David McFarlane

Hover or focus a month to see who was met.

What they lobby about

• Health12
• Intellectual Property8
• Science and Technology6
• Agriculture2
• Economic Development2
• Federal-Provincial Relations2
• Foreign Affairs1
• Government Procurement1
• Industry1
• International Trade1
• Research and Development1

The registry's own subject categories, chosen by the lobbyist on each filing. Each one opens its own page.

Who they met

Innovation, Science and Economic Development Canada (ISED) (4) · House of Commons (4) · Agriculture and Agri-Food Canada (AAFC) (4) · Health Canada (HC) (2) · Senate of Canada (1) · Privy Council Office (PCO) (1)

In their own words

• Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to- reimbursement and streamline federal/provincial listing processes Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
• Communicating with government officials on policies and/or programs that support life science research and development conducted in Canada, including manufacturing and workforce development, including measures pertaining to Canada’s Biomanufacturing and Life Sciences Strategy.
• Communicating with government officials on Bill S-243, An Act to establish a national framework for women’s health in Canada. Providing guidance, subject matter expertise and relevant information to help inform future policy development.